Compare Charles River Laboratories Intl. Inc (CRL) vs Carvana Co (CVNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Carvana Co — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Carvana Co trades at $63.73 (market cap $69.55B). The key difference: Carvana Co is far larger — about 4.9× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Carvana Co for 28 Days on average.
| CRL | CVNA | |
|---|---|---|
Market Cap | $14.23B | $69.55B |
Volume | 1,176,885 | 7,671,750 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $95.69 |
52-Week Low | $149.93 | $56.27 |
Typical Hold Time | 33 Days | 28 Days |
Enterprise Value | $17.06B | $72.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Carvana (CVNA) trades at $63.21, up 0.72% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 revenue up 52% and net income of $1.41 billion in 2025. Analyst sentiment is divided, with a consensus price target of $84.07, but technical indicators suggest near-term resistance at $64.
The outlook for CVNA hinges on sustained revenue growth and margin expansion, supported by operational improvements and capacity expansions. Key risks include high debt levels, competitive pressures, and sensitivity to interest rates. Upside potential exists if the company continues to exceed earnings expectations and expand its market share in the online used car sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →
